Neonatal lupus erythematosus: Difference between revisions
Mahmoud Sakr (talk | contribs) |
Mahmoud Sakr (talk | contribs) |
||
| Line 14: | Line 14: | ||
== Pathophysiology== | == Pathophysiology== | ||
Neonatal lupus is presumed to result from transplacental passage of maternal anti-SSA/Ro and/or anti-SSB/La antibodies. Ro and La molecules are thought to form a single particle that is present in all cells. The precise mechanism of injury to specific tissues, such as the skin and heart, is not known. | Neonatal lupus is presumed to result from transplacental passage of maternal anti-SSA/Ro and/or anti-SSB/La antibodies. Ro and La molecules are thought to form a single particle that is present in all cells. The precise mechanism of injury to specific tissues, such as the skin and heart, is not known. The auto antibodies are usually anti-SSA/Ro against usually 52kD or 60kD protein or anti-SSB/La against 48kD protein These auto antibodies later enter the myocardial cell causing exaggerated apoptosis which leads to expression of the antibodies on the surface of the cardiocyte. The same maternal antibodies recognize the antigens present in the neonatal skin exposed to UV light and high estradiol concentrations and cause the cutaneous manifestations of neonatal lupus. | ||
==Differentiating type page name here from other Diseases== | ==Differentiating type page name here from other Diseases== | ||
Revision as of 19:17, 26 August 2013
For patient information, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords:; NL; NLE; NLS, neonatal lupus; neonatal lupus syndrome
Overview
Neonatal lupus is a passively transferred autoimmune disease. It occurs in about 1 to 2 percent of babies born to mothers with autoimmune disease, primarily systemic lupus erythematosus (SLE) and Sjögren’s syndrome, and antibodies to SSA/Ro and/or SSB/La. The most serious complication of neonatal lupus is complete heart block.
Historical Perspective
The first case reported by Aylward in 1928, who described two siblings with complete heart block born to a mother who had Sjogren’s syndrome. Plant & Stevens described complete heart block as a manifestation of neonatal lupus in 1945.[1] But the first report linking autoimmune disease in mother with cutaneous lupus was McCuistion and Schoch in 1954. In 1957 Hogg noted the possible relation between autoimmune disease of the mother and congenital heart block in her child. Finally in 1980 Weston reported the association of neonatal lupus with maternal anti-Ro auto- antibodies.[2]
Pathophysiology
Neonatal lupus is presumed to result from transplacental passage of maternal anti-SSA/Ro and/or anti-SSB/La antibodies. Ro and La molecules are thought to form a single particle that is present in all cells. The precise mechanism of injury to specific tissues, such as the skin and heart, is not known. The auto antibodies are usually anti-SSA/Ro against usually 52kD or 60kD protein or anti-SSB/La against 48kD protein These auto antibodies later enter the myocardial cell causing exaggerated apoptosis which leads to expression of the antibodies on the surface of the cardiocyte. The same maternal antibodies recognize the antigens present in the neonatal skin exposed to UV light and high estradiol concentrations and cause the cutaneous manifestations of neonatal lupus.
Differentiating type page name here from other Diseases
Epidemiology and Demographics
The prevalence of Anti-SSA antibodies in women is 1:200 while the incidence of neonatal lupus is only 1 in 20,000 live births.[3] Only 1-2% of the infants of mothers with anti-SSA/Ro with or without anti-SSB/La antibodies develop neonatal lupus, although it ranges from 0.6% to 25% with an average of 7.2% by various studies. The incidence increases to 3% if the mother has anti- La antibodies in addition to anti- Ra antibodies. If the mother has also SLE along with anti-SSA antibodies the incidence of NLE may be up to 6-13%. This is much higher and reaches up to 25% if the mother already had a child with neonatal lupus. 15-20% present as complete heart block and 6% present as cutaneous lupus. The incidence of CHB is seen in 50-60% while the cutaneous lupus is seen in 25-30% and the combination of cutaneous and cardiac manifestations seen only in 4-10% of the patients with neonatal lupus.[4]
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Treatment
References
- ↑ PLANT RK, STEVEN RA (1945). "Complete A-V block in a fetus, case report". Am Heart J. 30: 615–8. PMID 21008284.
- ↑ Lee LA, Weston WL (1997). "Cutaneous lupus erythematosus during the neonatal and childhood periods". Lupus. 6 (2): 132–8. PMID 9061661.
- ↑ Neiman AR, Lee LA, Weston WL, Buyon JP (2000). "Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry". J Pediatr. 137 (5): 674–80. doi:10.1067/mpd.2000.109108. PMID 11060534.
- ↑ Eronen M, Sirèn MK, Ekblad H, Tikanoja T, Julkunen H, Paavilainen T (2000). "Short- and long-term outcome of children with congenital complete heart block diagnosed in utero or as a newborn". Pediatrics. 106 (1 Pt 1): 86–91. PMID 10878154.